Anti-PD-1/PD-L1 therapeutic response and survival in NSCLC are associated with PD-L1 tumour proportion score (TPS) measured using immunohistochemistry, a widely available and validated biomarker [2–7]. Here, PDCD1 is linked to neoplasm.